News Breaks |
|
|
| March 19, 2013 |
| 06:36 EDT |  | PTX | Pernix Therapeutics downgraded to Hold from Buy at Cantor
Cantor downgraded Pernix Therapeutics following the company's weaker than expected Q4 results and 2013 outlook. The firm lowered its price target for shares to $7 from $15. |
|
|
News For PTX From The Last 14 Days Check below for free stories on PTX the last two weeks. |
|
|
| May 13, 2013 |
| 07:48 EDT |  | PTX | Pernix Therapeutics shares could rebound on good execution, says Stifel
 Subscribe for More Information |
|
| May 10, 2013 |
| 08:18 EDT |  | PTX | Pernix Therapeutics appoints Michael Pearce as President and CEO
The company announced that the Board of Directors has appointed Mike Pearce, Pernix’s Chairman of the Board, to President and CEO of Pernix. Pearce will also remain as Chairman of the Board, but will step down as a member of the company’s Audit Committee. Cooper Collins will remain on the Board of Directors and serve as the company’s Chief Strategic Officer. |
|
| 08:17 EDT |  | PTX | Pernix Therapeutics sees FY13 revenue $90M-$100M, consensus $124.47M
Subscribe for More Information |
|
| 08:15 EDT | | PTX | Pernix Therapeutics reports Q1 EPS with items (23c), consensus (1c)
Reports Q1 revenue $22.1M, consensus $28.01M. Reports Q1 adjusted EBITDA ($1.4M), or (4c) per share. |
|
|
|
|
|
